GlassScriptPhysician profile
Frederick Gandolfo
NPI 1053550079
$5,602.73
in general payments reported to CMS, 2019-2025
32 companies · $1,723 in 2025
The $1,723 reported for 2025 was more than what 75% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $176 · 2021: $145 · 2022: $660 · 2023: $1,012 · 2024: $1,886 · 2025: $1,723.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,312 · Consulting Fee: $300 · Education: $9.24.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,311.85 |
| Consulting Fee | $300.00 |
| Education | $9.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,221.02 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $764.41 | 2019-2025 | Xifaxan, Trulance |
| Janssen Biotech, INC. | $387.51 | 2022-2025 | Stelara, Tremfya, Simponi |
| Madrigal Pharmaceuticals | $340.81 | 2024-2025 | Rezdiffra, Resmetirom |
| Takeda Pharmaceuticals U.S.A., INC. | $325.12 | 2021-2025 | Entyvio, Eohilia, Gattex |
| Echosens North America, INC. | $300.00 | 2024 | Fibroscan |
| Pfizer INC. | $278.57 | 2019-2025 | |
| Celgene Corporation | $274.56 | 2021-2024 | Zeposia |
| Phathom Pharmaceuticals, INC. | $249.88 | 2023-2025 | Voquezna |
| Ardelyx, INC. | $211.73 | 2022-2024 | Ibsrela |
| Lilly USA, LLC | $205.65 | 2024-2025 | Omvoh |
| Genzyme Corporation | $142.24 | 2023-2025 | |
| Regeneron Healthcare Solutions, INC. | $138.36 | 2023-2025 | Dupixent |
| Redhill Biopharma INC. | $127.72 | 2022-2024 | Talicia, Aemcolo, Movantik |
| Merck Sharp & Dohme LLC | $91.42 | 2022-2024 | Dificid |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $73.33 | 2022-2023 | Injectafer |
| Intercept Pharmaceuticals, INC. | $54.72 | 2022-2023 | Ocaliva |
| Ironwood Pharmaceuticals, INC | $44.28 | 2021-2024 | |
| Capsovision, INC. | $42.52 | 2024 | Capsocam Plus |
| Ipsen Biopharmaceuticals, INC | $41.43 | 2025 | Iqirvo |
| Celltrion USA INC. | $39.67 | 2024-2025 | Vegzelma, Zymfentra |
| Braintree Laboratories, INC. | $37.00 | 2025 | Sutab, Suflave |
| Concordia Pharmaceuticals INC. | $34.76 | 2019 | |
| Conmed Corporation | $26.88 | 2025 | Conmed Biopsy |
| Vivus LLC | $23.65 | 2024 | Qsymia |
| Exact Sciences Corporation | $21.29 | 2025 | Cologuard Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $21.19 | 2024 | Cyltezo |
| Aimmune Therapeutics, INC. | $21.17 | 2025 | Zenpep |
| Nestle Healthcare Nutrition INC. | $18.60 | 2023 | |
| Evoke Pharma, INC. | $17.73 | 2023 | Gimoti |
| Allergan, INC. | $16.27 | 2019 | |
| Janssen Pharmaceuticals, INC | $9.24 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Frederick Gandolfo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.